

AMENDMENT

Listing Of Claims:

Claims 1-20 (canceled).

Claim 21 (currently amended). A method for enhancing a humoral immune response in a mammal comprising ~~sequentially~~ administering a ~~the~~ protein chemokine MCP-4 and a nucleic acid encoding an antigen to said mammal, wherein said chemokine ~~is MCP-4~~ is administered prior to said nucleic acid.

Claim 22 (original). The method of claim 21 wherein said chemokine is recombinant.

Claim 23 (original). The method of claim 21 wherein said chemokine is human.

Claim 24 (original). The method of claim 21 further comprising administering a substance which allows for the slow release of said chemokine at a delivery site.

Claim 25 (canceled).

Claim 26 (canceled).

Claim 27 (previously presented). The method of claim 21 wherein said antigen is a tumor associated antigen.

Claim 28 (canceled).

Claim 29 (previously presented). The method of claim 21 wherein said antigen is a bacterial, viral or fungal antigen.

Express Mail Label: EV 533176825 US

Claim 30 (canceled).

Claim 31 (previously presented). The method of claim 27 wherein said tumor associated antigen is selected from the group consisting of Melan-A, tyrosinase, p97, β -HCG, GaINAc., MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-12, MART-1, MUC1, MUC2, MUC3, MUC4, MUC18, CEA, DDC, melanoma antigen gp75, Hker 8, high molecular weight melanoma antigen, K19, Tyr1 and Tyr2, members of the pMel 17 gene family, c-Met, PSA, PSM, α -fetoprotein, thyroperoxidase, gp 100, p53 and telomerase.

Claim 32 (canceled).

Claim 33 (previously presented). The method of claim 21 further comprising administering a combination of GM-CSF and IL-4.

Claim 34 (canceled).

Claim 35 (previously presented). The method of claim 21 further comprising administering a dendritic cell activating agent with said chemokine.

Claim 36 (previously presented). The method of claim 21 wherein said chemokine is administered intradermally, intramuscularly, subcutaneously, or topically.

Claims 37-68 (canceled).

Claim 69 (previously presented). The method of claim 35 wherein the activating agent is a nucleic acid containing an unmethylated CpG motif.